reports
SPS Commerce Appoints New Independent Directors to the Board
SPS Commerce Appoints New Independent Directors to the Board Enters into Cooperation Agreement with Anson Funds MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- SPS Commerce, Inc. (NASDAQ: SPSC), the leading intelligent supply chain network, announced today that its Board of Directors appointed Michael McConnell and Fumbi Chima as independent directors, effective immediately. Mr. McConnell previously served as a member of the SPS Board from 2018-19, and is an experienced director currently serving at several publicly traded companies, including Beonic, OneSpan, PowerFleet and QuickFee. M...
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financia...
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be ava...
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating...
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth qu...
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results: Q4 2025Q4 2024FY 2025FY 2024Revenue (in millions)$44.6$39.2$160.0$154.0Consumable revenue (in millions)$21.6$18.8$82.0$70.3Instrument revenue (in millions)$17.3$15.3$53.8$65.8Service and other revenue (in millions)$5.7$5.1$24.2$17.9RevioTM system placements21236197VegaTM system placements4271407Annualized Revio pul...
BBOT to Participate in Upcoming Investor Healthcare Conferences
BBOT to Participate in Upcoming Investor Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company’s participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. ET. Leerink Global Healthcare...
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Prov...
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI) In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-con...
Perimeter Announces Date for Fourth Quarter and Year End 2025 Earnings...
Perimeter Announces Date for Fourth Quarter and Year End 2025 Earnings Call CLAYTON, Mo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Perimeter Solutions (NYSE: ) (“Perimeter” or the “Company”), a leading provider of industrial products and services that support critical and complex customer missions across a range of niche applications, announced today it will release its financial results for the fourth quarter and year end 2025 on Thursday, February 26, 2026, before the market opens. The Company will host a conference call to discuss these results at 8:30 a.m. ET on the same day. The presentati...
Varonis to Present at Upcoming Investor Conference
Varonis to Present at Upcoming Investor Conference MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: VRNS), the leader in data security, announced its participation at the following upcoming conference: Morgan Stanley Technology, Media & Telecom Conference, March 2 – 5, in San Francisco. The presentation is scheduled for March 5 at 9:15 a.m. PT. The audio presentation will be webcast live and available by visiting the "Investor Relations" section of Varonis' website at . The webcast will be archived on the website for a limited time following the conference.Additional Resources For mo...
Arteris Announces Financial Results for the Fourth Quarter and Full Ye...
Arteris Announces Financial Results for the Fourth Quarter and Full Year 2025 and Estimated First Quarter and Full Year 2026 Guidance CAMPBELL, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the fourth quarter and year ended December 31, 2025 and provided estimated first quarter and full year 2026 guidance. “In the fourth quarter of 2025, we again delivered strong financial results, including a new record of Annual Contract Value plus roy...
Trupanion Reports Fourth Quarter & Full Year 2025 Results
Trupanion Reports Fourth Quarter & Full Year 2025 Results SEATTLE, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and full year ended December 31, 2025. “Since 2021, we’ve delivered more than $500 million in discretionary profit, growing at a 22% CAGR, including over $150 million last year alone,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “In 2025, we achieved our 15% annual margin target, while increasing subscription revenue ...
Flux Power Reports Fiscal Year 2026 Second Quarter Financial Results
Flux Power Reports Fiscal Year 2026 Second Quarter Financial Results VISTA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Flux Power Holdings, Inc. (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and software-driven electrification for commercial and industrial equipment, today reported financial and operational results for the 2026 fiscal second quarter ended December 31, 2025. Second Quarter and Recent Business Highlights Increased revenue 7.2% sequentially to $14.1 millionAchieved positive GAAP net income for the first time in its historySecured more ...
Roadzen Reports Strongest Quarter in Two Years with $14.4 Million Thir...
Roadzen Reports Strongest Quarter in Two Years with $14.4 Million Third Quarter Revenue and Sixth Consecutive Quarter of Adjusted EBITDA Improvement Roadzen delivers 18.8% revenue increase and reduces operating loss by 25.4% over prior-year quarter Strategic wins, new contracts and acquisitions, expand Roadzen’s U.S. market presence and full-stack operating capabilities, reinforcing its position as a global AI leader at the intersection of insurance and mobility Year-over-year Sequential Revenue Growth; Record Nine-Month RevenueQ3 revenue increased 18.8% over the prior-year quarter and 4....
Amwell® Announces Results for Fourth Quarter and Full Year 2025
Amwell® Announces Results for Fourth Quarter and Full Year 2025 BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. The company’s fourth quarter and full year 2025 earnings report can be viewed at . Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at . A webcast replay will be available for approxima...
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Fina...
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, February 26, 2026 at 4:30 p.m. ET to discuss the results. Inv...
Six Coherent Products Recognized by Lightwave Innovation Awards
Six Coherent Products Recognized by Lightwave Innovation Awards SAXONBURG, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, proudly announced that six of its products have received awards in the 2026 Lightwave Innovation Reviews, matching the Company’s achievement in 2025 and underscoring Coherent’s continued leadership in optical networking innovation. As compute infrastructure expands, from scale up and scale out architectures within the datacenter to long-reach data center interconnect, advances in the performance, integration, and ener...
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences to Participate in Upcoming Investor Conferences BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: Citi 2026 Virtual Oncology Leadership Summit, VirtualFebruary 19, 2026, with a fireside chat at 10:45 AM ET Leerink Global Healthcare Conference, Miami, FLMarch 10, 2026, with a fireside chat at 8:00 AM ET For more information and link to the Leerink webcast, please visit ...
Phillips Edison & Company Declares Monthly Dividends
Phillips Edison & Company Declares Monthly Dividends CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or “the Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that the Company’s Board of Directors declared monthly dividend distributions of $0.1083 per share of the Company’s common stock payable on April 1, 2026; May 1, 2026; and June 2, 2026 to stockholders of record as of March 16, 2026; April 15, 2026; and May 15, 2026, respectively. Operating ...
AvePoint to Participate in Upcoming Investor Conferences
AvePoint to Participate in Upcoming Investor Conferences JERSEY CITY, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AVPT; SGX: AVP), the global leader in AI data protection, unifying data security, governance, and resilience, today announced that members of the Company’s executive management team will present at the following investor conferences: Morgan Stanley TMT Conference (San Francisco, CA): Tuesday, March 3rd at 4:00pm PT2026 Cantor Global Technology & Industrial Growth Conference (New York, NY): Tuesday, March 10th at 11:20am ET In addition, AvePoint will attend the follow...
Celcuity Appoints Charles Romp to its Board of Directors
Celcuity Appoints Charles Romp to its Board of Directors MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. “Chip brings a wealth of oncology-related commercial expertise to our Board,” said Brian Sullivan, Ch...
Coherus Oncology, Inc. Announces Proposed Public Offering of Common St...
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per share less underwriting discounts and commissions. All of the shares in the Offering ar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.